
TURALIO is for adults with TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Systemic therapy for TGCT
Pexidartinib is the first FDA-approved, NCCN Category 1-recommended systemic therapy option for TGCT, also known as PVNS or GCT-TS1-41,2,4,5

In a clinical trial of 120 patients with advanced TGCT for whom surgery was not recommended, patients were randomized to placebo (n=59) or TURALIO (n=61) 1000 mg daily for 2 weeks followed by 400 mg twice daily. The efficacy outcomes measured at week 25 were ORR per RECIST v1.1, ORR per Tumor Volume Score (TVS), and mean change from baseline in ROM of the affected joint. The FDA-approved dose is 250 mg orally twice daily with a low-fat meal.1
In a clinical trial of 120 patients with advanced TGCT for whom surgery was not recommended, patients were randomized to placebo (n=59) or TURALIO (n=61) 1000 mg daily for 2 weeks followed by 400 mg twice daily. The efficacy outcomes measured at week 25 were ORR per RECIST v1.1, ORR per Tumor Volume Score (TVS), and mean change from baseline in ROM of the affected joint. The FDA-approved dose is 250 mg orally twice daily with a low-fat meal.1


Find a certified prescriber or treatment center
Our TGCT locator tool will help to guide your patient in the right direction.

TURALIO is for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
Pexidartinib is a Category 1 recommended therapy option* for TGCT/PVNS in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma4
*A Category 1 recommendation indicates that, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.4
TURALIO is the first systemic therapy for TGCT approved by the FDA in 2019.2
